---
title: "Suppression of Ovarian Function Trial"
slug: "suppression-of-ovarian-function-trial"
date: "2023-10-19"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[adjuvant endocrine therapy for breast cancer]]

# Suppression of Ovarian Function Trial

- SOFT and TEXT **è»Ÿå­—**çš„ â†’ çµæœï¼š[[Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer]]
  - July 12, 2018
  - N Engl J Med 2018; 379:122-137
  - DOI: 10.1056/NEJMoa1803164

1. Design: Randomized, phase III trial.
2. Number of patients: Not reported.
3. Patients characteristics: Women with hormone-receptor positive breast cancer.
4. Agents: Tamoxifen, exemestane, and ovarian suppression.
5. Treatment line: Adjuvant therapy after surgery and chemotherapy.
6. Trial Name/NCT Number: SOFT.
7. Comparison of three groups in a markdown table:

| Group/Outcome | Tamoxifen | Tamoxifen + ovarian suppression | Exemestane + ovarian suppression |
| --- | --- | --- | --- |
| 8-year Disease-Free Survival Rate | 78.9% | 83.2% | 85.9% |
| 8-year Overall Survival Rate | 91.5% | 93.3% | 92.1% |
| 8-year Overall Survival Rate (premenopausal patients after chemotherapy) | 85.1% | 89.4% | 87.2% |
| 8-year Rate of Distant Recurrence (HER2-negative patients who received chemotherapy) | Not reported | Lower with exemestane + ovarian suppression (by 7.0% in SOFT and by 5.0% in TEXT) | Not reported |
| Grade 3 or higher adverse events | 24.6% | 31.0% | 32.3% |
